// App-Quantinova.ai

287 : Emberger Syndrome with Concomitant GATA2, NPM1 and FLT3-ITD Mutations in Remission after Allogeneic Stem Cell Transplant

Researchers

Presenter

  • Abhijit Balkrishna Saste

Principal Investigators

  • Feng Jiang

  • Javier Arias-Stella III

  • Steven Gamalski

  • Edward Peres

  • Nalini Janakiraman

  • Shatha Farhan

Medical Centers

  • Hematology Oncology, Henry Ford Health System, Detroit, MI

  • Hematology/Oncology/Bone Marrow Transplant, Henry Ford Health System, Detroit, MI

  • Hematology/Oncology and Bone Marrow Transplantation, Henry Ford Hospital, Detroit, MI

  • Hematology Oncology, Henry Ford Health System, Detroit, MI

  • Department of Pathology and Laboratory Medicine, Henry Ford Health System, Detroit, MI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Pulmonary alveolar proteinosis

  • Lymphedema, primary, with myelodysplasia

  • Venous thrombosis

  • Myelodysplastic Syndrome

  • Hypothyroidism

  • Sarcoma

  • Graft-versus-host disease

  • Immunodeficiency 21

Biomarkers

  • Monocyte

  • Nucleophosmin 1

  • CCAAT enhancer binding protein alpha

  • Fms related tyrosine kinase 3

  • GATA-binding protein 2

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Ciprofloxacin

  • Azithromycin

  • Methotrexate

  • UK-109496

  • fludarabine tablet

  • Cytarabine liposomal

  • Idarubicin Hydrochloride

  • Tacrolimus

  • Acyclovir

  • Busulfan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved